CN104039781B - 西他生坦衍生物 - Google Patents

西他生坦衍生物 Download PDF

Info

Publication number
CN104039781B
CN104039781B CN201380005150.5A CN201380005150A CN104039781B CN 104039781 B CN104039781 B CN 104039781B CN 201380005150 A CN201380005150 A CN 201380005150A CN 104039781 B CN104039781 B CN 104039781B
Authority
CN
China
Prior art keywords
compound
acceptable salt
methyl
pharmacologically acceptable
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380005150.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN104039781A (zh
Inventor
田中圭悟
西冈大贵
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanitary Material R&d Management Co ltd
Original Assignee
Sanitary Material R&d Management Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanitary Material R&d Management Co ltd filed Critical Sanitary Material R&d Management Co ltd
Publication of CN104039781A publication Critical patent/CN104039781A/zh
Application granted granted Critical
Publication of CN104039781B publication Critical patent/CN104039781B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
CN201380005150.5A 2012-01-31 2013-01-29 西他生坦衍生物 Active CN104039781B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261592923P 2012-01-31 2012-01-31
US61/592923 2012-01-31
PCT/JP2013/051857 WO2013115162A1 (ja) 2012-01-31 2013-01-29 シタキセンタン誘導体

Publications (2)

Publication Number Publication Date
CN104039781A CN104039781A (zh) 2014-09-10
CN104039781B true CN104039781B (zh) 2016-08-17

Family

ID=48870751

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380005150.5A Active CN104039781B (zh) 2012-01-31 2013-01-29 西他生坦衍生物

Country Status (16)

Country Link
US (1) US8592470B2 (OSRAM)
EP (1) EP2810943B1 (OSRAM)
JP (1) JP6144631B2 (OSRAM)
KR (1) KR101933251B1 (OSRAM)
CN (1) CN104039781B (OSRAM)
AR (1) AR089838A1 (OSRAM)
AU (1) AU2013216122B9 (OSRAM)
BR (1) BR112014016204B1 (OSRAM)
CA (1) CA2861477C (OSRAM)
ES (1) ES2651293T3 (OSRAM)
IL (1) IL233171A (OSRAM)
IN (1) IN2014CN04945A (OSRAM)
MX (1) MX358151B (OSRAM)
RU (1) RU2622386C2 (OSRAM)
TW (1) TW201336496A (OSRAM)
WO (1) WO2013115162A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022297082B2 (en) * 2021-06-22 2024-04-18 Alchemedicine, Inc. Compound, endothelin A receptor antagonist and pharmaceutical composition
AR131023A1 (es) * 2022-11-11 2025-02-12 Alchemedicine Inc Compuesto, antagonista del receptor de endotelina a, antagonista del receptor de angiotensina ii de tipo 1 y composición farmacéutica
WO2024242594A1 (ru) * 2023-05-23 2024-11-28 Общество С Ограниченной Ответственностью "Ифар" Средство для лечения легочных гипертензий

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1184470A (zh) * 1995-04-04 1998-06-10 德州生物科技公司 调理内皮肽活性的噻吩基－、呋喃基－、吡咯基－与联苯磺酰胺及其衍生物
CN101730694A (zh) * 2007-04-10 2010-06-09 奥斯拜客斯制药有限公司 用于治疗高血压的取代的氘富集的噻吩

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861366A (en) 1984-08-27 1989-08-29 E. I. Du Pont De Nemours And Company Herbicidal acetals and ketals
US4753672A (en) 1985-07-16 1988-06-28 E. I. Du Pont De Nemours And Company Herbicidal acetals and ketals
US4659369A (en) 1984-08-27 1987-04-21 E. I. Du Pont De Nemours And Company Herbicidal acetals and ketals
TW224462B (OSRAM) * 1992-02-24 1994-06-01 Squibb & Sons Inc
JP4202649B2 (ja) * 1999-12-31 2008-12-24 エンサイシブ・ファーマシューティカルズ・インコーポレイテッド エンドセリンの活性を調節するスルホンアミドおよびそれらの誘導体
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1184470A (zh) * 1995-04-04 1998-06-10 德州生物科技公司 调理内皮肽活性的噻吩基－、呋喃基－、吡咯基－与联苯磺酰胺及其衍生物
CN101730694A (zh) * 2007-04-10 2010-06-09 奥斯拜客斯制药有限公司 用于治疗高血压的取代的氘富集的噻吩

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cytochrome P450 Enzymes Mechanism Based Inhibitors: Common Sub-Structures and Reactivity;E. Fontana et al.;《Current Drug Metabolism》;20051231;第6卷(第5期);413-454 *

Also Published As

Publication number Publication date
JP6144631B2 (ja) 2017-06-07
EP2810943B1 (en) 2017-09-27
MX358151B (es) 2018-08-07
AU2013216122A1 (en) 2014-07-24
BR112014016204A2 (pt) 2017-06-13
AU2013216122B2 (en) 2016-12-08
KR101933251B1 (ko) 2018-12-27
ES2651293T3 (es) 2018-01-25
US8592470B2 (en) 2013-11-26
RU2622386C2 (ru) 2017-06-15
CA2861477A1 (en) 2013-08-08
TW201336496A (zh) 2013-09-16
KR20140117455A (ko) 2014-10-07
US20130197045A1 (en) 2013-08-01
IL233171A (en) 2017-07-31
BR112014016204A8 (pt) 2017-07-04
EP2810943A1 (en) 2014-12-10
MX2014007619A (es) 2014-09-15
RU2014126427A (ru) 2016-03-20
WO2013115162A1 (ja) 2013-08-08
IN2014CN04945A (OSRAM) 2015-09-18
BR112014016204B1 (pt) 2020-09-24
EP2810943A4 (en) 2015-09-02
CN104039781A (zh) 2014-09-10
AR089838A1 (es) 2014-09-17
AU2013216122B9 (en) 2017-02-02
JPWO2013115162A1 (ja) 2015-05-11
IL233171A0 (en) 2014-07-31
CA2861477C (en) 2018-01-02

Similar Documents

Publication Publication Date Title
JP4836788B2 (ja) 未分化リンパ腫キナーゼ変調因子及びその使用法
EP3208269A1 (en) Inhibitors of c-fms kinase
WO2014036897A1 (zh) 咪唑啉类衍生物、其制备方法及其在医药上的应用
JP7353474B2 (ja) Ｉｒａｋ阻害剤、その製造方法及び用途
JP7487921B2 (ja) チロシンキナーゼ阻害剤及びその応用
WO2015069512A1 (en) PYRIDO[2,3-d]PYRIMIDIN-4-ONE COMPOUNDS AS TANKYRASE INHIBITORS
CN104039781B (zh) 西他生坦衍生物
CN116621859A (zh) 三并环类kat6抑制剂
CN106565674B (zh) 一种八氢环戊烷并[c]吡咯衍生物及其制备方法和在医药上的用途
CN110431138A (zh) Ar-v7抑制剂
CN104039777B (zh) 帕罗西汀衍生物
WO2013115167A1 (ja) アムバチニブ誘導体
JP2016003186A (ja) フタラン環含有アデノシンａ２ａ受容体拮抗薬
HK1242678A1 (en) Inhibitors of c-fms kinase

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant